Search
Amylyx Pharmaceuticals Inc
AMLXAdd to Watchlist
15.670USD
+0.420+2.75%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
1.74BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Amylyx Pharmaceuticals Inc is 8.83, ranking 53 out of 389 in the Biotechnology & Medical Research industry. The average price target is 20.00, with a high of 25.00 and a low of 16.00.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
23.400
Target Price
+49.33%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Amylyx Pharmaceuticals Inc
AMLX
12
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Amylyx Pharmaceuticals Inc's price target?
Analysts forecast that Amylyx Pharmaceuticals Inc's price target is USD 20.00, with the highest forecast at USD 25.00 and the lowest forecast at USD 16.00.
How have Amylyx Pharmaceuticals IncAMLX's recent earnings per share performed?
The market expectation was USD -0.37, while Amylyx Pharmaceuticals IncAMLX's earnings per share (EPS) for the previous quarter was USD -0.30. EPS for the next quarter is expected at USD -0.36.
What is the analyst rating for Amylyx Pharmaceuticals Inc?
Based on the ratings of Amylyx Pharmaceuticals Inc's stock from 12 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
